Oridonin induces human melanoma A375-S2 cell death partially through inhibiting insulin-like growth factor 1 receptor signaling

Journal of Asian Natural Products Research

Volumn 10, Issue 8, 2008, Pages 777-788

  Wang, Hong Jun ^a   Li, Dan ^a   Yang, Fan Yi ^a   Tashiro, Shin Ichi ^b   Onodera, Satoshi ^b   Ikejima, Takashi ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

A375 S2 cells; IGF 1; IGF 1R; Oridonin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; MANUMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; ORIDONIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIFITHRIN ALPHA; RAS PROTEIN; SOMATOMEDIN C RECEPTOR; WORTMANNIN;

AGAR GEL ELECTROPHORESIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG INHIBITION; DRUG POTENTIATION; DRUG STRUCTURE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

RABDOSIA RUBESCENS;

EID: 49449103167     PISSN: 10286020     EISSN: 14772213     Source Type: Journal    
DOI: 10.1080/10286020802030918     Document Type: Article

References (18)

1. M.Y. Xia, M.W. Wang, Z. Cui, S.I. Tashiro, S. Onodera, M. Minami, and T. Ikejima, J. Asian Nat. Prod. Res. 8, 335 (2006).
2. Y. Zhang, Q.H. Zhang, L.J. Wu, S. Onodera, and T. Ikejima, J. Asian Nat. Prod. Res. 6, 19 (2004).
3. Q. Cui, S.I.Tashiro, S. Onodera, and T. Ikejima, J. Pharmacol. Sci. 101, 230 (2006).
4. Y.Q. Liu, S. You, S.I. Tashiro, S. Onodera, and T. Ikejima, J. Pharmacol. Sci. 98, 361 (2005).
5. T. Ikezoe, S.S. Chen, X.J. Tong, D. Heber, H. Taguchi, and H.P. Koeffler, Int. J. Oncol. 23, 1187 (2003).
6. C.L. Zhang, L.J. Wu, S.I. Tashiro, S. Onodera, and T. Ikejima, Chin. Pharmacol. Bull. 20, 669 (2004).
7. C.L. Zhang, L.J. Wu, H.J. Zuo, S.I. Tashiro, S. Onodera, and T. Ikejima, J. Pharmacol. Sci. 96, 155 (2004).
8. C.L. Zhang, L.J. Wu, S.I. Tashiro, S. Onodera, and T. Ikejima, J. Asian Natl. Prod. Res. 6, 127 (2004).
9. M. Pollak, E.S. Schernhammer, and S.E. Hankinson, Nat. Rev. Cancer 4, 505 (2004).
10. H.M. Khandwala, I.E. McCutcheon, A. Flyvbjerg, and K.E. Friend, Endocr. Rev. 21, 215 (2000).
11. H. Yu and T. Rohan, J. Natl. Cancer Inst. 92, 1472 (2000).
12. Y. Wang and Y. Sun, Curr. Cancer Drug Targets 2, 191 (2002).
13. L. Kanter-Lewensohn, A. Dricu, L. Girnita, J. Wejde, and O. Larsson, Growth Factors 17, 193 (2000).
14. M. Resnicoff, D. Coppola, C. Sell, R. Rubin, S. Ferrone, and R. Baserga, Cancer Res. 54, 4848 (1994).
15. M.J. Garnett, S. Rana, H. Paterson, D. Barford, and R. Marais, Mol. Cell 20, 963 (2005).
16. C. Ohlsson, N. Kley, H. Werner, and D. LeRoith, Endocrinology 139, 1101 (1998).
17. J. Luo, B.D. Manning, and L.C. Cantley, Cancer Cell 4, 257 (2003).
18. J. Reuben, C. Shaw, and L. Cantley, Nature 441, 424 (2006).